Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
Rhea-AI Summary
Seres Therapeutics (Nasdaq:MCRB) announced that management will present a company overview at the H.C. Wainwright 4th Annual BioConnect Investor Conference at 3:30 p.m. ET on May 19, 2026.
A live webcast and replay will be available via the company’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – MCRB
In the May 12 session, MCRB gained 1.53%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 05 | Q1 2026 earnings | Negative | -2.5% | Reported Q1 2026 net loss and limited cash runway to Q3 2026. |
| May 04 | Preclinical data | Positive | +1.1% | Presented supportive SER-603 preclinical data at DDW 2026. |
| Apr 20 | Clinical data update | Positive | +0.6% | Showcased SER-155 Phase 1b and translational data at ESCMID Global. |
| Apr 09 | Conference participation | Neutral | -0.6% | Announced participation in CARB-X Investor Day with platform overview. |
| Mar 12 | FY 2025 earnings | Positive | +1.3% | Reported FY 2025 net income and cash of $45.8M with runway to Q3 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent earnings and scientific updates have generally seen modest, directionally aligned price reactions.
Over the last few months, Seres reported Q4 2025 and Q1 2026 results, emphasizing its microbiome pipeline and cash runway into Q3 2026. Scientific updates highlighted SER-155 and SER-603 data and presentations at ESCMID Global 2026 and DDW 2026. The stock’s reactions to these earnings and data events, typically within a few percent of unchanged, suggest the market has responded in a measured way to both clinical and financial developments.
Key Terms
live biotherapeutics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference and will present a company overview at 3:30 p.m. ET on May 19, 2026.
A live webcast of the presentation will be accessible through the “Events and Presentations” tab on the “Investors and News” section of the Company’s website at http://www.serestherapeutics.com and will be available for replay following the event.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics, with a focus on inflammatory and immune diseases. The Company led the development and FDA approval of VOWST™, the first orally administered microbiome therapeutic, which was subsequently divested to Nestlé Health Science. SER-155, which has received Breakthrough Therapy and Fast Track designations, is being advanced for patients undergoing allogeneic hematopoietic stem cell transplant, and is Phase 2 ready, pending receipt of funding. An investigator-sponsored trial of SER-155 is ongoing in immune checkpoint inhibitor–related enterocolitis to further evaluate the potential breadth of the Company’s live biotherapeutic platform. SER-603, in development for inflammatory bowel disease, is designed to modulate the gastrointestinal microbiome and support mucosal barrier integrity by targeting inflammatory bacteria and associated metabolites. For more information, please visit www.serestherapeutics.com.
Investor and Media Contact:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
